Table 3. Adverse events considered related to study treatment (CDX-1401, resiquimod, and/or poly-ICLC).

Table includes all adverse events reported with a possible, probable, or definite relationship to any of the study treatments, occurring in more than one patient. No grade 3, 4, or 5 events have been reported as potentially related to study treatment.

CDX-1401plus topical
resiquimod (cohorts 1–3;
n = 23), n (%)
CDX-1401plus poly-ICLC
(cohort 4; n = 7),
n (%)
CDX-1401plus subcutaneous
resiquimod (cohort 5;
n = 7), n (%)
CDX-1401plus poly-ICLC
and subcutaneous
resiquimod (cohort 6; n = 8),
n (%)
Administration
site reaction
18 (78)5 (71)5 (71)7 (88)
Fatigue5 (22)3 (43)2 (29)1 (13)
Nausea2 (9)0 (0)0 (0)2 (25)
Chills1 (4)1 (14)0 (0)2 (25)
Influenza-like illness2 (9)1 (14)0 (0)0 (0)
Decreased appetite3 (13)0 (0)0 (0)0 (0)
Arthralgia2 (9)0 (0)0 (0)1 (13)
Myalgia0 (0)0 (0)2 (29)1 (13)
Pyrexia1 (4)1 (14)0 (0)0 (0)
Hemoglobin
decreased
2 (9)0 (0)0 (0)0 (0)
Dizziness1 (4)0 (0)0 (0)1 (13)